Phase 1b study of pan‐AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN‐mutated advanced solid tumors
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34733
Abstract: In this first‐in‐human phase 1b study (ClinicalTrials.gov identifier NCT02761694) of advanced solid tumors with PIK3CA/AKT/PTEN mutations, the authors investigated the safety and efficacy of the pan‐AKT inhibitor vevorisertib (MK‐4440; ARQ 751) as monotherapy or with… read more here.
Keywords: pan akt; pik3ca akt; solid tumors; phase study ... See more keywords